107 related articles for article (PubMed ID: 6370875)
1. Use of ceftazidime in the treatment of severe localized and systemic infections.
Gabrielli GB; Corrocher R; De Sandre G
Int J Clin Pharmacol Ther Toxicol; 1984 Mar; 22(3):167-9. PubMed ID: 6370875
[TBL] [Abstract][Full Text] [Related]
2. Position of ceftazidime in respiratory diseases.
Ando' F; Girbino G; Ferrara F
Drugs Exp Clin Res; 1985; 11(6):369-72. PubMed ID: 3915288
[TBL] [Abstract][Full Text] [Related]
3. Cefsulodin and ceftazidime, two antipseudomonal cephalosporins.
Smith BR
Clin Pharm; 1984; 3(4):373-85. PubMed ID: 6380902
[TBL] [Abstract][Full Text] [Related]
4. [Correlation between pulmonary pharmacokinetics and pharmacodynamics support the hypothesis of the usefulness of ceftazidime at a single 1g daily dose in the treatment of bacterial exacerbation of chronic obstructive bronchopneumonia with moderate functional damage].
Cazzola M; Noschese P; Vinciguerra A; Di Perna F; Califano C; Berra A
Minerva Med; 1998; 89(1-2):15-22. PubMed ID: 9561021
[TBL] [Abstract][Full Text] [Related]
5. Antibiotic use in neonatal sepsis.
Yurdakök M
Turk J Pediatr; 1998; 40(1):17-33. PubMed ID: 9722468
[TBL] [Abstract][Full Text] [Related]
6. Cefepime: a new fourth-generation cephalosporin.
Okamoto MP; Nakahiro RK; Chin A; Bedikian A; Gill MA
Am J Hosp Pharm; 1994 Feb; 51(4):463-77; quiz 541-2. PubMed ID: 8017411
[TBL] [Abstract][Full Text] [Related]
7. [Clinical trial of a new broad-spectrum cephalosporin: HR 756 (cefotaxime)].
Poletti T; Bertola D; Pellerito R; Soragna A
Minerva Med; 1980 Jul; 71(27):1935-43. PubMed ID: 6248823
[TBL] [Abstract][Full Text] [Related]
8. Ceftazidime in pediatric infections unsuccessfully treated with other antibiotics: an evaluation of its efficacy and tolerability in compromised host.
Boner AL; Castellani C; Fostini R; Padovani E
Int J Clin Pharmacol Ther Toxicol; 1986 Jun; 24(6):333-6. PubMed ID: 2942496
[TBL] [Abstract][Full Text] [Related]
9. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
10. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
Deal EN; Micek ST; Reichley RM; Ritchie DJ
Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
[TBL] [Abstract][Full Text] [Related]
11. Third-generation cephalosporins: a critical evaluation.
Barriere SL; Flaherty JF
Clin Pharm; 1984; 3(4):351-73. PubMed ID: 6432420
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of isepamicin and ceftazidime compared with amikacin and ceftazidime in acute lower respiratory tract infection.
Colardyn F
J Chemother; 1995 Jun; 7 Suppl 2():129-35. PubMed ID: 8622101
[TBL] [Abstract][Full Text] [Related]
13. Ceftazidime--a new extended-spectrum cephalosporin.
Gozzard DI; Geddes AM; Farrell ID; Eykyn SJ; Phillips I; Wise R; Brown RM
Lancet; 1982 May; 1(8282):1152-6. PubMed ID: 6122940
[TBL] [Abstract][Full Text] [Related]
14. Ceftazidime in severe infections: a Swiss multicentre study.
Francioli P; Clément M; Geroulanos S; von Graevenitz A; Luthy R; Regamey C; Stalder H; Vogt M; Waldvogel FA
J Antimicrob Chemother; 1983 Jul; 12 Suppl A():139-46. PubMed ID: 6225761
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of cefepime in the treatment of serious bacterial infections in hospitalized adult patients.
Sheng WH; Wang JT; Chang SC
J Microbiol Immunol Infect; 2000 Jun; 33(2):109-14. PubMed ID: 10917881
[TBL] [Abstract][Full Text] [Related]
16. Local and general treatment with ceftazidime as monotherapy in central nervous system infections and in septicemic infection.
Fiori GP; Dietz A; Montanari M; Torre D
Int J Clin Pharmacol Ther Toxicol; 1985 Jun; 23(6):326-8. PubMed ID: 3894254
[TBL] [Abstract][Full Text] [Related]
17. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review.
Lorente L; Jiménez A; Palmero S; Jiménez JJ; Iribarren JL; Santana M; Martín MM; Mora ML
Clin Ther; 2007 Nov; 29(11):2433-9. PubMed ID: 18158083
[TBL] [Abstract][Full Text] [Related]
18. In vitro properties of ceftazidime, a highly active broad-spectrum cephalosporin with antipseudomonal activity.
Harper PB
Clin Ther; 1984; 6(4):411-24. PubMed ID: 6432324
[TBL] [Abstract][Full Text] [Related]
19. Cephacetrile--a new cephalosporin antibiotic.
Hodson AH; Holloway WJ
Int J Clin Pharmacol; 1973 Feb; 7(1):89-94. PubMed ID: 4699390
[No Abstract] [Full Text] [Related]
20. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.
McKinnon PS; Paladino JA; Schentag JJ
Int J Antimicrob Agents; 2008 Apr; 31(4):345-51. PubMed ID: 18313273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
